Salarius Pharmaceuticals Inc (NAS:SLRX)

$ 1.67 0.0065 (0.39%) Market Cap: 2.41 Mil Enterprise Value: -558,000.00 PE Ratio: 0 PB Ratio: 0.82 GF Score: 29/100

Salarius Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference Transcript
Sep 29, 2022
Q2 2022 Salarius Pharmaceuticals Inc Earnings Call Transcript
Aug 08, 2022

$44 (+9.95%)

Earnings
Q1 2022 Salarius Pharmaceuticals Inc Earnings Call Transcript
May 12, 2022

$44.4 (+38.75%)

Earnings
Q4 2021 Salarius Pharmaceuticals Inc Earnings Call Transcript
Mar 10, 2022

$100 (+33.40%)

Earnings
Salarius Pharmaceuticals Inc Asset Acquisition Agreement with DeuteRx LLC - M&A Call Transcript
Jan 13, 2022
Q3 2021 Salarius Pharmaceuticals Inc Earnings Call Transcript
Nov 04, 2021

$167.02 (-1.14%)

Earnings
Salarius Pharmaceuticals Inc at Benzinga Healthcare Small Cap Conference (Virtual) Transcript
Sep 29, 2021
Q2 2021 Salarius Pharmaceuticals Inc Earnings Call Transcript
Aug 05, 2021

$160.54 (+0.97%)

Earnings
Salarius Pharmaceuticals Inc Virtual KOL & Investor Event Call Transcript
Jun 21, 2021
Q1 2021 Salarius Pharmaceuticals Inc Earnings Call Transcript
May 12, 2021

$230 (-4.17%)

Earnings
Q4 2020 Salarius Pharmaceuticals Inc Earnings Call Transcript
Mar 18, 2021

$300 (-5.06%)

Earnings
Salarius Pharmaceuticals Inc to Discuss Advancements in the Phase 1/2 Clinical Trial of Seclidemstat Conference Call Transcript
Feb 24, 2021
Q3 2020 Salarius Pharmaceuticals Inc Earnings Call Transcript
Nov 11, 2020

$152.76 (+2.55%)

Earnings
Q2 2020 Salarius Pharmaceuticals Inc Earnings Call Transcript
Aug 12, 2020

$214 (-4.46%)

Earnings
Q1 2020 Salarius Pharmaceuticals Inc Earnings Call Transcript
May 14, 2020

$167.96 (+0.87%)

Earnings
Salarius Pharmaceuticals Inc at SNN Network Transcript
Nov 20, 2019

Salarius Pharmaceuticals Inc to Discuss Advancements in the Phase 1/2 Clinical Trial of Seclidemstat Conference Call Transcript

Feb 24, 2021 / 01:30PM GMT

Release Date Price: $426 (+10.36%)

Transcript

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the [Status] Clinical Update -- I'm sorry, the Salarius Clinical Update Call.

At this time, all participants are in a listen only mode. After the speakers' presentation, we will have a question-and-answer session. (Operator Instructions).

At this time, I would like to turn the conference over today to Mr. Jason Rando. Please go ahead, sir.

Jason Rando

Tiberend Strategic Advisors, Inc. - EVP & COO

Good morning, everyone, and thank you for joining today's conference call. Earlier this morning Salarius Pharmaceuticals issued a press release announcing the initiation of the expansion phase of its ongoing Phase 1/2 Clinical Trial for Seclidemstat in relapsed and refractory Ewing sarcoma and Ewing-related sarcoma patients. The press release can be found in the news section of the salariuspharma.com.

Before beginning today's call, I would like to make the following statement. Today, we'll be making forward-looking statements about future expectations, plans, events and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.